💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Finasteride

CHEMBL710 Phase 4 承認済み Small molecule
Half-Life
5-6 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
372.5 g/mol
LogP
3.0
Phase
4

By inhibiting the type II 5-alpha-reductase enzyme that converts testosterone into the more potent dihydrotestosterone, finasteride reduces a hormone that drives prostate growth and male-pattern hair loss. It shrinks an enlarged prostate to relieve urinary symptoms and, at a lower dose, slows scalp hair loss. Marketed as Proscar and Propecia, the steroid derivative has the formula C23H36N2O2.

This medication works by blocking an enzyme that converts testosterone into a more potent hormone called dihydrotestosterone, which drives prostate growth and male-pattern hair loss. It is used to shrink an enlarged prostate and relieve urinary symptoms, as well as to treat male hair loss.

分子量

372.5490 g/mol

LogP

3.00

TPSA

58.20 Ų

リピンスキーの五則

適合

治療領域

Benign Prostatic Hyperplasia Endocrinology Urology

薬物分類

G — G - Genito-Urinary System and Sex Hormones

作用機序

Competitive inhibitor of 5-alpha-reductase type II.

Pharmacokinetics (PK)

Half-Life 5-6 hours

Pharmacodynamics (PD)

機序

Competitive inhibitor of 5-alpha-reductase type II.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C

                

                

                
                

                    
InChI

                    
InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C23H36N2O2

                    

                    
                    

                        
HBD / HBA

                        
2 / 2

                    

                    
                    

                        
回転可能結合数

                        
2

                    

                    
                    
                    

                        
重原子数

                        
27

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Finasteride + Tamsulosin
                            
                        

                        
                        
Finasteride and tamsulosin are deliberately combined (as Duodart/Jalyn) for BPH treatment; the combination provides additive symptom relief with no significant adverse pharmacokinetic interaction.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Finasteride + Fluconazole
                            
                        

                        
                        
Fluconazole inhibits CYP3A4, which contributes to finasteride metabolism; co-administration may modestly increase finasteride plasma concentrations, though the clinical significance is generally low.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Finasteride + Doxycycline
                            
                        

                        
                        
No clinically significant pharmacokinetic or pharmacodynamic interaction is established between doxycycline and finasteride; they are occasionally co-prescribed in patients with androgenetic alopecia and concomitant infections.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
This medication works by blocking an enzyme that converts testosterone into a more potent hormone called dihydrotestosterone, which drives prostate growth and male-pattern hair loss. It is used to shrink an enlarged prostate and relieve urinary symptoms, as well as to treat male hair loss.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Competitive inhibitor of 5-alpha-reductase type II.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Finasteride: Half-life: 5-6 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Finasteride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Sildenafil
                            Small molecule
                        
                        
                        
                            Tamsulosin
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL710.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 57363.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.